Capital Guardian Trust’s West Pharmaceutical WST Stock Holding History

Capital Guardian Trust’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-60	Closed	-$7K	–	474
2018 Q3	$7K	Buy	+60	New	+$6.73K	﹤0.01%	487

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Capital Guardian Trust's WST Position: Q4 2018 in Review

Capital Guardian Trust sold out of West Pharmaceutical (WST) in Q4 2018, closing a stake of 60 shares — an estimated $7K sold.

Capital Guardian Trust first reported a position in WST in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 355 funds tracked by Wall St. Rank hold WST as of Q4 2018.

Capital Guardian Trust reported no remaining West Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Capital Guardian Trust sold 60 West Pharmaceutical shares in Q4 2018, an estimated $7K.
Capital Guardian Trust first reported a position in West Pharmaceutical in Q3 2018 and held it in 1 quarter.
Capital Guardian Trust's West Pharmaceutical position peaked at $7K in Q3 2018.
355 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2018.

Based on Capital Guardian Trust's 13F filing for Q4 2018, filed 14 Feb 2019.